9 withdrawn, 5 terminated, 4 completed, 1 recruiting. 19 Phase 2, 9 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Withdrawn 9, Terminated 5, Completed 4, Recruiting 1 |
| Phase 1 | 9 | Withdrawn 4, Completed 3, Terminated 2 |
Follow devimistat: new trials by email Literature Review of devimistat trials Research Report on devimistat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) CPI 613, Metformin, Blood draws - Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2024-12-01 | 2024-09-19 | |
| Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer CPI-613, modified Folfirinox - Pancreatic Cancer Stage IV | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2024-08-15 | 2024-08-15 | |
| Trial of Devimistat in Combination With Modified FOLFIRINOX in Patients With Metastatic Adenocarcinoma of the Pancreas Devimistat, Modified FOLFIRINOX - Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | University of Michigan Rogel Cancer Center | 2023-07-01 | 2023-08-02 | |
| CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors Biospecimen Collection, Computed Tomography, Devimistat - Advanced Biliary Tract Carcinoma, Advanced Colorectal Carcinoma | Phase 2 | Recruiting | Northwestern University | 94 | 2023-03-08 | 2023-03-10 |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome CPI-613, Hydroxychloroquine - Myelodysplastic Syndromes, Progressive Disease | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2021-05-01 | 2021-04-14 | |
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) CPI 613, Gemcitabine, Cisplatin - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | University of Michigan Rogel Cancer Center | 75 | 2020-06-23 | 2025-12-31 |
| A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations CPI-613 - Lymphoma, Leukemia | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 24 | 2018-12-31 | 2026-08-27 |
| CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer CPI 613, Oxaliplatin, Irinotecan - Pancreatic Cancer | Phase 1 / Phase 2 | Completed | David Bajor, MD | 49 | 2018-12-07 | 2025-01-23 |
| CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer CPI-613, mFOLFIRNOX - Pancreatic Ductal Adenocarcinoma | Phase 2 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-08-01 | 2025-04-29 | |
| CPI-613 and Docetaxel in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer 6,8-Bis(benzylthio)octanoic Acid, Docetaxel, Pharmacological Study - Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7 | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2018-06-01 | 2018-08-01 | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome CPI-613 - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS) | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2016-01-01 | 2016-12-29 | |
| 6,8-Bis(Benzylthio)Octanoic Acid, Cytarabine, and Daunorubicin Hydrochloride in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia 6,8-Bis(benzylthio)octanoic Acid, Cytarabine, Daunorubicin Hydrochloride - Untreated Adult Acute Myeloid Leukemia | Phase 1 / Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2015-12-01 | 2018-07-03 | |
| Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic Cancer CPI-613, Gemcitabine, Any non-gemcitabine chemotherapies or best supportive care - Metastatic Pancreatic Adenocarcinoma | Phase 2 | Withdrawn | Cornerstone Pharmaceuticals | 2014-01-01 | 2013-08-14 | |
| CPI-613 in Treating Patients With Myelodysplastic Syndromes Who Failed Previous Therapy 6,8-bis(benzylthio)octanoic acid - Previously Treated Myelodysplastic Syndromes | Phase 2 | Terminated | Wake Forest University Health Sciences | 12 | 2013-08-01 | 2024-10-17 |
| Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients CPI-613 - Cancer | Phase 2 | Terminated | Cornerstone Pharmaceuticals | 7 | 2013-06-01 | 2016-12-29 |
| CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery 6,8-bis(benzylthio)octanoic acid - Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer | Phase 1 / Phase 2 | Completed | Wake Forest University Health Sciences | 17 | 2013-05-01 | 2019-05-15 |
| A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients CPI-613, Gemcitabine - Cancer, Pancreatic Cancer | Phase 1 / Phase 2 | Terminated | Cornerstone Pharmaceuticals | 6 | 2009-05-01 | 2017-03-21 |
Pancreatic Neoplasms (4) · Neoplasms (3) · Carcinoma, Hepatocellular (2) · Leukemia, Myeloid, Acute (2) · Lung Neoplasms (2) · Myelodysplastic Syndromes (2) · Neoplasm Metastasis (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Bile Duct Neoplasms (1) · Biliary Tract Neoplasms (1) · Breast Neoplasms (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1)
Wake Forest University Health Sciences (7) · Cornerstone Pharmaceuticals (6) · University of Michigan Rogel Cancer Center (2) · David Bajor, MD (1) · Memorial Sloan Kettering Cancer Center (1) · Northwestern University (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (17)
King C Lee, Ph.D. (3) · Bayard Powell, MD (2) · Timothy Pardee (2) · Ariela Noy, MD (1) · Avi Retter, M.D. (1) · Caio Rocha Lima, MD (1) · David Bajor, MD (1) · Devalingam Mahalingam (1) · Jordan Winter, MD (1) · Neil Senzer, M.D. (1) · Rakhee Vaidya, M.B.B.S. (1) · Stefan Grant (1) · Vaibhav Sahai (1) · Vaibhav Sahai, MBBS, MS (1)
P30CA012197 (7), P30CA060553 (1)